Up and Coming
This feature highlights changes in clinical research organizations’ personnel.
Abbott has named Robert Ford chief executive officer, effective March 31, 2020. Ford was most recently appointed president and chief operating officer at the company.
Neil Cooper has been named chief financial officer at Abingworth LLP. Cooper previously served as finance director at Kennet Partners Ltd.
Arrowhead Pharmaceuticals, Inc. has named Javier San Martin chief medical officer and Curt Bradshaw chief scientific officer. San Martin recently served as senior vice president and head of global clinical development at Ultragenyx. Bradshaw was president and CSO at Tollnine.
Fuad Ahmad has been appointed interim chief financial officer at Cutera, Inc. Ahmad is a partner at FLG Partners.
Andy Busch has been appointed chief innovation officer at Cyclerion Therapeutics, Inc. Busch previously served as head of research and development at Shire.
Dalrada Health has appointed Payal Keswarpu chief medical officer. Keswarpu last served as clinical lead for oncology informatics and genomics at Philips in India.
Diverse Biotech has named Stella Vnook chief executive officer. Vnook was most recently vice president of managed markets and trade at Assertio Therapeutics, Inc.
David Altarac has been appointed chief medical officer at Entasis Therapeutics Holdings Inc. Altarac was most recently senior vice president, head of regulatory, safety R&D quality and compliance
EyePoint Pharmaceuticals, Inc. has named George Elston chief financial officer and head of corporate development. Elston was formerly CFO and head of corporate development at Enzyvant Therapeutics.
Thomas Caskey has been appointed chief medical officer at Human Longevity, Inc. Caskey is a professor of molecular and human genetics at the Baylor College of Medicine, and past president of the American Society of Human Genetics and Human Genome Organization.
Inozyme Pharma has named Pedro Huertas chief medical officer, Gus Khursigara vice president of medical affairs and operations and Catherine Nester vice president of physician and patient strategies. Huertas was most recently CMO of Sentien Pharmaceuticals. Khursigara is the former vice president of global medical affairs at Biohaven Pharmaceuticals. Nester was senior oncology business director at Incyte Pharmaceuticals.
Insmed Inc. has appointed Roger Adsett chief operating officer. Adestt was most recently chief commercial officer with the company.
Ipsen has expanded its senior management team with the appointment of Howard Mayer as chief of research and development. Mayer was most recently senior vice president, chief medical officer and head of research and development at Shire’s neuroscience division.
iQ Group Global
Jonathan Arambula has been appointed vice president of research at OncoTEX Inc., a member company of iQ Group Global. Arambula was previously a research associate and lecturer in the department of chemistry at the University of Texas.
Ian Wendt has been named vice president of commercial strategy at Jaguar Health. Wendt previously led strategy and tactical development for a national team focused on policy and protocol development within HIV at Gilead Sciences.
Jenny Klein-Sosa has been named chief research officer at mytaptrack. Klein-Sosa is a psychologist and neuropsychological evaluator for the Integrated Center for Child Development, and previously served as chief executive officer of GENED Educational Services, LLC.
Christine Ring has been named general counsel, Christiana Guiducci head of immunology and oncology research, Jean Chang head of clinical program management and asset strategy and Gwenn Hansen senior vice president of research at Nurix Therapeutics, Inc. Ring was previously senior vice president of legal at Dermira, Inc. Guiducci previously served as vice president of oncology research at Dynavax Technologies. Change was oncology project lead and vice president of corporate development at Dynavax Technologies. Hansen was previously the senior director of drug discovery technologies with Nurix before her promotion.
Rentschler Biopharma SE has expanded its leadership team with the addition of Hermant Kumar as vice president for process sciences and Lorraine Blackman as head of human resources for the U.S. Kumar was previously senior vice president of process development and manufacturing operations at AnaptysBio. Blackman was director of human resources at IDT Biologika.
Badrul Chowdhury has been named chief medical officer at Savara Inc. Chowdhury was previously senior vice president and chief physician scientist for respiratory, inflammation and autoimmunity late stage development in biopharmaceuticals research and development at AstraZeneca.
David Coman has been appointed chief medical officer at Science 37, a company that specializes in fully decentralized clinical trials. Coman previously served as chief strategy officer and lead of data and analytics business at ERT.
Sema4 has named Joel Sendek chief financial officer. Sendek was formerly CFO at Spero Therapeutics.
Daniel Stevens has been named chief medical officer at Theragnostics Inc. Stevens’ most recent appointment was as a global development lead at Ipsen.
Verisys has appointed Srini Chillara chief technology officer. Chillara was most recently vice president of software development at Experience Healthcare.
Vireo Health has named Shaun Nugent chief financial officer and Amber Shimpa chief administrative officer. Nugent previously served as managing director at 16Vente Advisors. Shimpa was most recently CFO at Vireo Health.
Yumanity Therapeutics has appointed Brigitte Robertson chief medical officer. Robertson was most recently vice president of global clinical development and therapeutic area head within Shire’s neuroscience division.